Adagio Medical Appoints Deborah Kaster as Chief Business Officer
Adagio Medical (ADGM) has appointed Deborah Kaster as Chief Business Officer, bringing over 25 years of leadership experience in medical technology. Kaster previously served as VP of Investor Relations at Shockwave Medical, where she contributed to the company's 2000% stock price appreciation from IPO to Johnson & Johnson acquisition.
At Adagio, Kaster will oversee business development, strategic partnerships, investor relations, and corporate communications. Her notable achievements include leading Kyphon's $725 million acquisition of St. Francis Medical Technologies, which led to Kyphon's subsequent $4 billion acquisition by Medtronic.
Adagio Medical specializes in Ultra-Low Temperature Cryoablation (ULTC) technology for cardiac arrhythmias treatment. The company's vCLAS catheter, designed for ventricular tachycardia treatment, is CE Marked and currently under evaluation in the FULCRUM-VT U.S. IDE Pivotal Study.
Adagio Medical (ADGM) ha nominato Deborah Kaster come Chief Business Officer, portando con sé oltre 25 anni di esperienza nella leadership nel settore della tecnologia medica. Kaster ha precedentemente ricoperto il ruolo di VP delle Relazioni con gli Investitori presso Shockwave Medical, dove ha contribuito all'aumento del prezzo delle azioni dell'azienda del 2000% dall'IPO all'acquisizione da parte di Johnson & Johnson.
In Adagio, Kaster supervisionerà lo sviluppo commerciale, le partnership strategiche, le relazioni con gli investitori e le comunicazioni aziendali. Tra i suoi risultati notevoli c'è la guida all'acquisizione di St. Francis Medical Technologies da parte di Kyphon per 725 milioni di dollari, che ha portato all'acquisizione successiva di Kyphon da parte di Medtronic per 4 miliardi di dollari.
Adagio Medical si specializza nella tecnologia di Criobrazione a Ultra-Bassa Temperatura (ULTC) per il trattamento delle aritmie cardiache. Il catetere vCLAS dell'azienda, progettato per il trattamento della tachicardia ventricolare, è marcato CE ed è attualmente in fase di valutazione nello studio pivotale FULCRUM-VT IDE negli Stati Uniti.
Adagio Medical (ADGM) ha nombrado a Deborah Kaster como Directora de Negocios, aportando más de 25 años de experiencia en liderazgo en tecnología médica. Kaster anteriormente se desempeñó como VP de Relaciones con Inversores en Shockwave Medical, donde contribuyó a la apreciación del precio de las acciones de la compañía del 2000% desde la OPI hasta la adquisición por parte de Johnson & Johnson.
En Adagio, Kaster supervisará el desarrollo comercial, las asociaciones estratégicas, las relaciones con los inversores y las comunicaciones corporativas. Sus logros notables incluyen liderar la adquisición de St. Francis Medical Technologies por parte de Kyphon por 725 millones de dólares, lo que llevó a la posterior adquisición de Kyphon por Medtronic por 4 mil millones de dólares.
Adagio Medical se especializa en la tecnología de Crioblasia a Ultra-Baja Temperatura (ULTC) para el tratamiento de arritmias cardíacas. El catéter vCLAS de la compañía, diseñado para el tratamiento de la taquicardia ventricular, tiene marca CE y actualmente está siendo evaluado en el estudio pivotal FULCRUM-VT IDE en los EE. UU.
Adagio Medical (ADGM)는 Deborah Kaster를 최고 사업 책임자로 임명하여 의료 기술 분야에서 25년 이상의 리더십 경험을 가져왔습니다. Kaster는 이전에 Shockwave Medical에서 투자자 관계 부사장으로 재직하며, IPO부터 Johnson & Johnson의 인수까지 회사의 주가가 2000% 상승하는 데 기여했습니다.
Adagio에서 Kaster는 사업 개발, 전략적 파트너십, 투자자 관계 및 기업 커뮤니케이션을 감독하게 됩니다. 그녀의 주목할 만한 성과 중 하나는 Kyphon이 St. Francis Medical Technologies를 7억 2500만 달러에 인수하도록 이끌었으며, 이는 Kyphon이 Medtronic에 의해 40억 달러에 인수되는 결과로 이어졌습니다.
Adagio Medical은 심장 부정맥 치료를 위한 초저온 냉동 절제(ULTC) 기술을 전문으로 하고 있습니다. 회사의 vCLAS 카테터는 심실성 빈맥 치료를 위해 설계되었으며, CE 마크를 받았고 현재 미국의 FULCRUM-VT IDE 주요 연구에서 평가 중입니다.
Adagio Medical (ADGM) a nommé Deborah Kaster au poste de Directrice Générale des Affaires, apportant plus de 25 ans d'expérience en leadership dans la technologie médicale. Kaster a précédemment occupé le poste de VP des Relations Investisseurs chez Shockwave Medical, où elle a contribué à l'appréciation de 2000 % du prix des actions de l'entreprise, de l'IPO à l'acquisition par Johnson & Johnson.
Chez Adagio, Kaster supervisera le développement commercial, les partenariats stratégiques, les relations avec les investisseurs et les communications d'entreprise. Parmi ses réalisations notables figure la direction de l'acquisition de St. Francis Medical Technologies par Kyphon pour 725 millions de dollars, qui a conduit à l'acquisition subséquente de Kyphon par Medtronic pour 4 milliards de dollars.
Adagio Medical se spécialise dans la technologie de Cryoablation à Ultra-Basse Température (ULTC) pour le traitement des arythmies cardiaques. Le cathéter vCLAS de l'entreprise, conçu pour le traitement de la tachycardie ventriculaire, est marqué CE et est actuellement en évaluation dans l'étude pivot FULCRUM-VT IDE aux États-Unis.
Adagio Medical (ADGM) hat Deborah Kaster zur Chief Business Officer ernannt und bringt über 25 Jahre Führungserfahrung im Bereich Medizintechnologie mit. Zuvor war Kaster VP für Investor Relations bei Shockwave Medical, wo sie zur Steigerung des Aktienkurses des Unternehmens um 2000% vom Börsengang bis zur Übernahme durch Johnson & Johnson beigetragen hat.
Bei Adagio wird Kaster die Geschäftsentwicklung, strategische Partnerschaften, Investor Relations und Unternehmenskommunikation leiten. Zu ihren bemerkenswerten Leistungen gehört die Leitung der 725 Millionen Dollar schweren Übernahme von St. Francis Medical Technologies durch Kyphon, die zur anschließenden Übernahme von Kyphon durch Medtronic für 4 Milliarden Dollar führte.
Adagio Medical spezialisiert sich auf die Technologie der Kryoablation bei ultratiefen Temperaturen (ULTC) zur Behandlung von Herzrhythmusstörungen. Der vCLAS-Katheter des Unternehmens, der für die Behandlung von ventrikulärer Tachykardie entwickelt wurde, ist CE-gekennzeichnet und wird derzeit in der FULCRUM-VT IDE-Pivotal-Studie in den USA evaluiert.
- Appointment of experienced CBO with proven track record in medical technology sector
- New CBO's previous success in driving 2000% stock appreciation at Shockwave Medical
- Strategic M&A expertise demonstrated through $725M St. Francis Medical acquisition
- CE Mark approval for vCLAS catheter
- Company still in clinical trial phase for U.S. market with FULCRUM-VT study
Most recently, Kaster served as Vice President of Investor Relations at Shockwave Medical, where she played a pivotal role in the company’s growth from IPO to its acquisition by Johnson & Johnson. During her time at Shockwave, the company’s stock price appreciated nearly
Kaster's career spans a wide range of roles where she has consistently demonstrated her ability to drive corporate strategy and business development. As Director of Business Development at Kyphon, she led the company in a competitive bidding process for St. Francis Medical Technologies, which resulted in Kyphon’s successful
“Debbie’s deep expertise in corporate strategy, business development and communications, combined with her relationships and experience on Wall Street, will be instrumental as Adagio Medical enters its next phase of growth,” said Todd Usen, Chief Executive Officer of Adagio Medical. “We are thrilled to welcome Debbie to the team and are confident that her leadership will drive value for our stakeholders and accelerate our mission to revolutionize treatment for patients with ventricular tachycardia.”
At Adagio Medical, Kaster will oversee business development, strategic partnerships, investor relations and corporate communications, working as part of the senior leadership team to advance the company’s objectives and vision.
“I am excited to join Adagio Medical at such a transformative time for the company,” said Kaster. “The potential to make a meaningful impact in the EP space is immense, and I look forward to contributing to Adagio’s success and helping drive the company’s growth strategy.”
Kaster’s distinguished career includes senior roles at Gilmartin Group and in the medical technology investment banking group at Piper Jaffray. She has advised and led strategic initiatives for numerous public and private companies in the medical technology sector. Kaster holds an MBA in Finance and Strategic Management from The Wharton School at the University of
About Adagio Medical
Adagio Medical is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (“ULTC”) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular tachycardia ("VT") with its purpose-built vCLAS catheter, which is CE Marked and is currently under evaluation in the FULCRUM-VT
View source version on businesswire.com: https://www.businesswire.com/news/home/20250331268869/en/
Caroline Corner, PhD
ICR Healthcare
IR@adagiomedical.com
Source: Adagio Medical
FAQ
What experience does Deborah Kaster bring to Adagio Medical (ADGM)?
What will be Deborah Kaster's role as CBO at Adagio Medical (ADGM)?
What is Adagio Medical's (ADGM) main technology focus?
What is the current status of Adagio Medical's (ADGM) vCLAS catheter?
